Unleashing the Potential of Immuno-Oncology Therapies June 5, 2025 © 2025 Xilio Therapeutics, Inc. 1 Forward-Looking Statements and Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timing and expectations related to: development timelines and anticipated milestones for Xilio's programs; the receipt of future contingent payments under Xilio's coll ...

Group 1 - The recommendation for ServiceNow (NYSE: NOW) is a buy rating, indicating a positive outlook for the company's stock [1] - The growth potential for ServiceNow is strong, with expectations of a 20% revenue compound annual growth rate (CAGR) driven by AI monetization and vertical expansion [1] - The investment strategy focuses on long-term investments while also considering short-term opportunities to uncover alpha, emphasizing a bottom-up analysis of individual companies [1]

Core Insights - Iris Energy (NASDAQ: IREN) has evolved from a small renewable-powered miner to one of the largest clean-energy data-center operators globally, significantly expanding its footprint since its listing in late 2021 [1] Company Overview - The company has focused on building a substantial clean-energy data-center infrastructure, leveraging renewable energy sources to support its operations [1] Industry Context - The growth of Iris Energy reflects a broader trend in the industry towards sustainable and renewable energy solutions, particularly in the data center sector, which is increasingly prioritizing energy efficiency and environmental responsibility [1]

2025 年初以来受益AIOT、机器人需求，增收增利、降本增效效果显著。2025Q1 单季营收1.91 亿元， 同比+105.63%；归母净利润2,431.50 万元，同比增加5,309.57 万元；季度归母净利率12.7%。2025Q1 奥 比中光在AIoT 领域业务呈现较快增长态势，通过持续构建全价值链成本管控体系，进一步推动研发效 能与运营模式升级，成功实现经营利润由负转正。2025 年4-5 月，营收1.72 亿元，同比+131.63%；归母 净利润3,068.50 万元，同比增加约3,334.29 万元；归母净利率17.8%。 全球3D 视觉传感器重要供应商之一，应用于生物识别、三维扫描、机器人等。奥比中光专注3D 视觉感 知技术研发，构建了"全栈式技术研发能力+全领域技术路线布局"的3D视觉感知技术体系，主要产品包 括3D 视觉传感器、消费级应用设备和工业级应用设备，在生物识别、机器人、三维扫描、AIoT、工业 三维测量等市场上实现多项代表性商业应用。 投资要点： 公告：2025 年1-5 月营收3.63 亿元，同比+117.18%；归母净利润5500 万元，同比增加8,643.86 万元。 上调 ...

Core Viewpoint - Medifast, Inc. (NYSE: MED) is initiated with a Strong Buy rating and a price target of $56, focusing on its weight management and nutritional products under the OPTAVIA brand [1] Company Overview - Medifast, Inc. manufactures and distributes weight management products and nutritional products, primarily under the OPTAVIA brand [1] Research Methodology - Moretus Research employs a structured, repeatable framework to identify companies with durable business models, mispriced cash flow potential, and intelligent capital allocation [1] - The research combines rigorous fundamental analysis with a high-signal, judgment-driven process, avoiding noise and overly complex forecasting [1] - Valuation is based on sector-relevant multiples tailored to each company's business model and capital structure, emphasizing comparability, simplicity, and relevance [1] Investment Focus - Research coverage favors underappreciated companies undergoing structural change or temporary dislocation, where dispassionate analysis can lead to asymmetric returns [1] - Moretus Research aims to provide professional-grade insights, actionable valuation, and a strong filter for what truly matters in modern equity analysis [1]

NGN-401 for Rett Syndrome - NGN-401, a gene therapy leveraging EXACT transgene regulation technology, is being developed for Rett syndrome [15] - Rett syndrome affects an estimated 6,000-9,000 patients in the U S [20] - The worldwide incidence of Rett syndrome is estimated at 1 in 10,000 females [20] - Phase 1/2 data showed durable improvements, including a two-point improvement in CGI-I in all participants [38] - All four participants in the Phase 1/2 trial achieved a CGI-I rating of "Much Improved" [41] - The company expects to announce additional Phase 1/2 clinical data in the second half of 2025 [64] Clinical Trial and Regulatory Updates - The FDA has accepted the conversion of the Phase 1/2 trial to a registrational trial for NGN-401 [28] - The Embolden registrational trial is designed as an open-label, single-arm, baseline-controlled study [27] - The proposed number of participants in the Embolden trial is 18, subject to FDA feedback [28] - The company anticipates providing a regulatory update regarding the registrational trial in the first half of 2025 [64] Manufacturing and Financials - Neurogene has a 42,000 sq ft in-house AAV manufacturing facility in Houston, with 6,000 sq ft of cleanrooms [11] - The company's cash runway is expected to fund operations into early 2028 [6, 64]

Group 1 - Akeso, Inc. has successfully enrolled the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4, marking its first bispecific ADC to enter clinical trials [1] - AK146D1 has received approvals from the U.S. FDA, Australia's TGA, and China's NMPA to begin clinical trials, indicating strong regulatory support for the product [1] - Akeso is the only company globally with two approved cancer immunotherapy bispecific antibodies, cadonilimab and ivonescimab, establishing a strong leadership advantage in the IO+ADC space [2] Group 2 - ADC therapeutics are a key component of Akeso's "IO+ADC" 2.0 strategy, which aims to reshape the global treatment landscape and set new standards for cancer care [3] - The company emphasizes the potential of innovative bispecific ADCs like AK146D1 to unlock global clinical opportunities and enhance cancer therapies [4] - Trop2 and Nectin4 are ideal targets for ADC therapy due to their high expression in various tumor types and low expression in normal tissues, which may improve treatment efficacy [4][5] Group 3 - AK146D1 is the first bispecific ADC targeting both Trop2 and Nectin4, with preclinical studies showing strong anti-tumor activity and favorable safety profiles [5] - The development of AK146D1 holds significant potential for improving treatment outcomes for cancer patients, highlighting Akeso's commitment to advancing cancer therapies [5]

创新适老化金融服务，五位一体服务体系引关注 随着我国老年人口呈快速增长态势，养老金融服务需求日益凸显。国家卫健委老龄司数据显示，2035年 左右，我国60岁及以上老年人口将突破4亿人，在总人口中的占比将超过30%，进入重度老龄化阶段。 面对老龄化趋势，泸州银行积极响应，精心打造"移动+陪伴+远程+上门+安全"五位一体养老金融服务 体系，其中针对老年群体推出的"适老版"手机银行更是成为展会一大亮点。该版本以老年用户需求为核 心，操作简单、省心省力，通过升级视觉交互，放大字体、简洁布局，将账户查询、转账汇款、理财产 品、生活缴费等核心功能清晰呈现。 近日，2025年中国国际金融展在上海盛大启幕。这场金融界的盛会，吸引了来自全国各地超300家机构 踊跃参与，涵盖国内外金融机构、科技企业及行业组织。在众多参展机构中，泸州银行(01983.HK)作为 我国西南地区地级市首家上市银行，以亮眼姿态携多项金融科技新成果惊艳亮相，全方位展示了其在普 惠金融、养老金融、金融科技及协同建设西部金融中心四大核心板块的创新实践与卓越成果，适老化移 动银行等在内的一系列创新应用更是成为展会焦点。 展会现场，泸州银行的展台重点呈现的新一代 ...

今天(7月3日)下午，在全体会议上，韩国国会通过戒严法修正案。新法案规定：在宣布戒严后，包括军 方以及警方等在内的任何人将不得妨碍国会议员和国会工作人员出入以及会议进行。新法案对于军警人 员进入国会也进行了限制，要求除非在国会的要求或允许下，军警人员不得随意进入国会，违者将被追 究刑事责任或处以罚金。另外，新法案还要求，总统在发起戒严、召集国务会议审议时应同步进行会议 记录，并在通报国会时提交相关资料。韩国舆论分析，此举旨在避免再次出现时任总统尹锡悦去年底发 动紧急戒严时军方及警方人员闯入国会并阻碍议事进行等情况。(CCTV国际时讯) ...

南方共同市场第66届领导人峰会开幕 智通财经7月3日电，据央视新闻报道，当地时间7月2日，南方共同市场及伙伴国第66届领导人峰会在轮 值主席国阿根廷首都布宜诺斯艾利斯开幕，峰会为期2天，首脑会议于3日举行。2日中午起，南方共同 市场成员国以及伙伴国国家领导人陆续抵达布宜诺斯艾利斯，将出席3日举办的首脑会议，巴西总统卢 拉也确认出席，这是自米莱就任阿根廷总统以来，卢拉首次前往阿根廷。会上将宣布巴西接替阿根廷担 任南共市轮值主席国，任期至今年12月31日。 ...